Setmelanotide: A Novel Targeted Treatment for Monogenic Obesity
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Pharmacy Technology"
DOI: 10.1177/87551225221116010
Abstract: Objective: To review clinical data regarding the newly approved drug setmelanotide, an injectable melanocortin 4 receptor (MC4R) agonist, for chronic weight management in adults and children aged 6 years and older with monogenic obesity. Data… read more here.
Keywords: setmelanotide; obesity setmelanotide; phase; obesity ... See more keywords